A science advisory from the American Heart Association recommended that prescription n-3 fatty acids (eicosapentaenoic acid [EPA]+docosahexaenoic acid [DHA] or EPA-only) at a dose of 4 g/d (>3 g/d total EPA+DHA) are an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents (https://www.ahajournals.org/). AstraZeneca announced that compared to placebo, dapagliflozin (a SGLT2 inhibitor) significantly reduced cardiovascular death or the worsening of heart failure (HF, defined as hospitalization or an urgent HF visit) in patients with and without type 2 diabetes with reduced ejection fraction on standard of care treatment (https://www.astrazeneca-us.com/). Data from a US community‐based cohort of 12 168 middle‐aged adults suggest that diets higher in plant foods and lower in animal foods were associated with a lower risk of cardiovascular morbidity and mortality in a general population (https://www.ahajournals.org/).
